Relay Therapeutics, Inc.

Developing precision oncology medicines using structure-based drug discovery. Zovegalisib (RLY-2608) is in a Phase 3 breast-cancer trial and a Phase 1/2 vascular-anomalies program.

Back to company catalog

Precision oncology · Structure-based small molecules · Phase 3 / Phase 1-2

Compare report options